Enbrel Indications/Uses

Adults with Rheumatoid Arthritis: Treatment of signs and symptoms and inhibiting the progression of structural damage in adult patients with moderately to severely active rheumatoid arthritis. ENBREL can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone.
Paediatric Patients with Juvenile Idiopathic Arthritis: Treatment of polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate.
Treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate.
Treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy.
Adults with Psoriatic Arthritis: ENBREL is indicated for reducing signs and symptoms of active arthritis in adult patients with psoriatic arthritis. ENBREL can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone.
Axial Spondyloarthritis: Adults with Ankylosing Spondylitis (AS): Treatment of signs and symptoms of active ankylosing spondylitis in adults who have had an inadequate response to conventional therapy.
Adults with Non-radiographic Axial Spondyloarthritis: ENBREL is indicated for the treatment of adults with severe non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated CRP and/or MRI evidence, who have had an inadequate response to non-steroidal anti-inflammatory drugs (NSAIDs).
Adults with Plaque Psoriasis: Treatment of adults with moderate to severe chronic plaque psoriasis who failed to respond to, or who have contraindications to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or PUVA.
Paediatric Patients with Plaque Psoriasis: ENBREL is indicated for the treatment of chronic severe plaque psoriasis in children and adolescents from the age of 6 years who are inadequately controlled by, or are intolerant to other systemic therapies or phototherapies.